deleobuvir sodium
- Generic Name
- deleobuvir sodium
Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT02182401
Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 75
- Registration Number
- NCT02176525
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT01605461
- Locations
- 🇺🇸
1241.22.001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT01528735
- Locations
- 🇯🇵
1241.25.002 Boehringer Ingelheim Investigational Site, Kofu, Yamanashi, Japan
🇯🇵1241.25.001 Boehringer Ingelheim Investigational Site, Omura, Nagasaki, Japan
🇯🇵1241.25.005 Boehringer Ingelheim Investigational Site, Kurashiki, Okayama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath